Close Menu

Memorial Sloan-Kettering

Deleterious NOTCH mutations may predict more favorable immune checkpoint responses in lung cancer patients without EGFR or ALK mutations.

A study evaluated data from a Phase I/II trial of Piqray combined with an aromatase inhibitor to find mechanisms of resistance hindering clinical benefit from the therapy.

In NSCLC driven by MET exon 14 alterations, research indicates Xalkori had some activity.

Clonal hematopoiesis variants appear to outnumber tumor mutations in the plasma of most cancer patients, the investigators found in their study.

Researchers found that about 12 percent to 15 percent of breast cancer patients carry multiple mutations in the gene, 95 percent of which are double mutations.

In a study, patients with class 3 BRAF mutations were more likely to respond to an anti-EGFR antibody treatment as a first-or second-line therapy.

The company said it has seen progress in efforts to get FDA approval for its tissue and liquid biopsy tests as data continues to accumulate for pan-cancer utility.

A finding that not all BRCA-mutated tumors are likely to respond to PARP inhibitors should make doctors more cautious when prescribing them off label.

The grant recipients will receive up to $5 million each and are led by scientists at institutions including Harvard Medical School and the Cleveland Clinic.

Though some experts prefer the comprehensive nature of whole-genome sequencing, others find whole-exome sequencing or targeted exome panels to be more useful.

Pages